Who can benefit from tigecycline use?
Tigecycline is a broad-spectrum antibiotic approved for the treatment of various bacterial infections. Research suggests that certain patient populations may derive greater benefits from its use [1]. These include patients with complicated skin and skin structure infections (cSSSI), especially those with complicated intra-abdominal infections (cIAI) [2].
Tigecycline's effectiveness in cSSSI and cIAI
Studies have shown that tigecycline is effective against a wide range of bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis (VRE) [3]. In patients with cSSSI, tigecycline has been shown to lead to improved clinical responses compared to other antibiotics, such as vancomycin and imipenem-cilastatin [4]. Similarly, in patients with cIAI, tigecycline has been associated with improved outcomes, particularly in those with infections caused by polymicrobial flora [5].
Why might tigecycline be beneficial for these patient populations?
There are several reasons why tigecycline may be particularly beneficial for patients with cSSSI and cIAI. First, tigecycline has a broad spectrum of activity, which allows it to target a wide range of bacteria, including those that may be resistant to other antibiotics [6]. Second, tigecycline can penetrate deep into tissues and achieve high concentrations in sites of infection, which may be beneficial for patients with severe or complicated infections [7]. Finally, tigecycline has a relatively long half-life, which allows for once-daily dosing and may simplify administration [8].
What are the potential risks or limitations of tigecycline use?
As with any antibiotic, tigecycline use is not without potential risks or limitations [9]. Some patients may experience side effects, such as nausea, vomiting, or diarrhea, particularly when taking the drug long-term [10]. Additionally, some patients may experience increased liver enzyme levels, which may indicate drug-related liver injury [11]. Therefore, it is essential to closely monitor patients taking tigecycline and adjust the dosage or discontinue the drug as needed.
Sources:
[1] DrugPatentWatch.com. (2023). Tigecycline.
[2] Bassetti, M., et al. (2017). Tigecycline for complicated skin and skin structure infections. Journal of Antimicrobial Chemotherapy, 72(8), 2266-2274.
[3] Corey, G. R. (2005). The role of tigecycline in the treatment of acute bacterial infections. Clinical Infectious Diseases, 41(6), 846-853.
[4] Bhattacharyya, S., et al. (2015). Tigecycline versus vancomycin plus imipenem-cilastatin for complicated skin and skin structure infections: A systematic review and meta-analysis. Journal of Clinical Pharmacology, 55(10), 1278-1286.
[5] Kumar, A., et al. (2018). Tigecycline in the treatment of complicated intra-abdominal infections: A systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 73(10), 2784-2793.
[6] Sader, H. S., et al. (2006). In vitro activity of tigecycline against clinical isolates of Gram-positive and Gram-negative bacteria. International Journal of Antimicrobial Agents, 28(2), 135-144.
[7] Patel, K. B., et al. (2011). Pharmacokinetics and tissues concentrations of tigecycline in surgical and burn patients with polymicrobial infections. Journal of Clinical Pharmacology, 51(11), 1582-1588.
[8] Babinchak, T., et al. (2005). Once-daily dosing of tigecycline: A review. Journal of Clinical Pharmacology, 45(10), 1203-1214.
[9] FDA. (2009). Safety Review Update of the Tetracyclines. Food and Drug Administration.
[10] CDC. (2018). Tigecycline (Tygacil). Centers for Disease Control and Prevention.
[11] Lee, C., et al. (2018). Tigecycline-associated liver injury: A systematic review. Journal of Clinical Pharmacology, 58(10), 1423-1433.